Skip to main content
TipRanks
Go Ultimate75% OFF

Burcon Nutrascience (BRCNF) AI Stock Analysis

66 Followers
BRCNF

Burcon Nutrascience

(Other OTC:BRCNF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue Growth and PipelineStrong recent revenue growth, together with a broad 209-project funnel, indicates expanding commercial adoption of Burcon’s protein offerings. This provides multiple routes to future sales growth and reduces reliance on any single customer or product launch over the coming quarters.
Negative Factors
Severe UnprofitabilityCosts currently exceed revenue by a wide margin, with deeply negative gross, operating and net margins. Although revenue is growing, the scale of losses shows that commercialization has not yet produced sustainable economics and could require substantial improvement before profitability becomes durable.

Burcon Nutrascience (BRCNF) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%BRCNF-60.14%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.99M
Dividend Yield
―
Average Volume (3M)
3,585
Price to Earnings (P/E)
-0.6
Beta (1Y)
0.28
Revenue Growth
382.10%
EPS Growth
-14.89%
Country
US
Employees
14
Sector
Consumer Defensive
Sector Strength
62
Industry
Packaged Foods

Burcon Nutrascience Business Overview & Revenue Model

Company Description

Burcon NutraScience Corporation, along with its associated entities, is a Canadian enterprise specializing in the development and commercialization of plant-derived proteins and functional ingredients for the food and beverage sectors. Its extensive...

Burcon Nutrascience Earnings Call Summary

Earnings Call Date:Nov 16, 2026(Q2-2027)|% Change Since:-7.25%|Next Earnings Date:Aug 07, 2019
Earnings Call SentimentPositive

The call was strongly optimistic, supported by nearly threefold year-over-year revenue growth, more than 40 buying customers, 209 active projects, improving production performance, insider financing support and expectations for significant Q3 growth, positive cash flow and a $10-plus million run rate in calendar 2027. The main negatives were an 18% sequential revenue decline, second-quarter infrastructure-related production constraints, a temporary slowdown in new customer onboarding, an ongoing operating loss and an external financing raise that remains in progress. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Year-Over-Year Revenue Growth
Fiscal Q2 2027 revenue increased nearly threefold relative to the prior year's comparable quarter, driven predominantly by growing sales of Burcon's protein offerings.

Negative Updates

Sequential Revenue Decline
Fiscal Q2 2027 revenue declined 18% sequentially from Q1 due to the timing of shipments late in Q1 and the timing of the production ramp and additional infrastructure required.

Company Guidance

Management expects to see significant sequential quarter-over-quarter growth in Q3 and described a path to a $10-plus million run rate, meaningful operating leverage and positive cash flow into calendar 2027, with positive cash flow inside of calendar 2027 and 2027 a breakout year; 1/3 of growth is expected from existing customers and existing products, 1/3 most likely from existing customers launching a new product, a new flavor, a new SKU, and the last part from new customers with new projects, while 26 of 209 active projects are past the pallet order stage and are expected to drive near-term growth in early to mid-2027. The company is currently running a 5-day 24-hour a day operation and plans to move to a 7-day, 24-hour a day operation in the coming months.

Burcon Nutrascience Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

BRCNF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
TSE:NPRATSE:NPRA49NeutralCAD 36.57M-26.1130.14%―32.91%55.73%
TSE:CULTTSE:CULT38UnderperformCAD 789.24K-0.46-9999.00%―3288.96%50.66%

* Consumer Defensive Sector Average

Performance Comparison

0%200%400%600%BRCNFTSE:DTEATSE:NPRATSE:CULTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BRCNF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BRCNFBurcon Nutrascience Corporation0.55-0.84-60.43%
TSE:DTEADavidstea Inc.1.200.2729.03%
TSE:NPRANepra Foods, Inc.0.290.18168.18%
TSE:CULTCult Food Science Corp.0.32-0.18-36.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.